NYSE:VNRX VolitionRx (VNRX) Stock Price, News & Analysis $0.73 0.00 (0.00%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends About VolitionRx Stock (NYSE:VNRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VolitionRx alerts:Sign Up Key Stats Today's Range$0.70▼$0.7550-Day Range$0.49▼$0.8852-Week Range$0.43▼$1.23Volume68,345 shsAverage Volume165,243 shsMarket Capitalization$67.21 millionP/E RatioN/ADividend YieldN/APrice Target$2.50Consensus RatingModerate Buy Company OverviewVolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Read More… DeFi Coin on Verge of Breakout! (Ad)Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… VolitionRx Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks27th Percentile Overall ScoreVNRX MarketRank™: VolitionRx scored higher than 27% of companies evaluated by MarketBeat, and ranked 886th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingVolitionRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVolitionRx has only been the subject of 1 research reports in the past 90 days.Read more about VolitionRx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of VolitionRx is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VolitionRx is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for VNRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVolitionRx does not currently pay a dividend.Dividend GrowthVolitionRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for VNRX. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for VolitionRx this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added VolitionRx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, VolitionRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.80% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.09% of the stock of VolitionRx is held by institutions.Read more about VolitionRx's insider trading history. Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address VNRX Stock News HeadlinesVolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.comOctober 13, 2024 | americanbankingnews.comVolition to share new 'NETs in sepsis management' data insights at upcoming webinarOctober 9, 2024 | prnewswire.comCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …October 18, 2024 | Weiss Ratings (Ad)Volition hosts NETs in sepsis management symposium at ESICM Lives 2024October 3, 2024 | prnewswire.comVolition Appoints Dr. Ethel Rubin as an Independent DirectorSeptember 30, 2024 | prnewswire.comVolition Hosts KOL Roundtable on SepsisSeptember 11, 2024 | prnewswire.comVolitionRx Limited (VNRX) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | seekingalpha.comVolitionRx Limited Announces Second Quarter 2024 Financial Results and Business UpdateAugust 14, 2024 | prnewswire.comSee More Headlines VNRX Stock Analysis - Frequently Asked Questions How have VNRX shares performed this year? VolitionRx's stock was trading at $0.7170 on January 1st, 2024. Since then, VNRX shares have increased by 1.8% and is now trading at $0.7298. View the best growth stocks for 2024 here. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSE:VNRX) announced its earnings results on Wednesday, August, 14th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The company earned $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of VolitionRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include BlackRock Innovation and Growth Term Trust (BIGZ), FS KKR Capital (FSK), Guggenheim Strategic Opportunities Fund (GOF), 3M (MMM), OFS Credit (OCCI), XAI Octagon Floating Rate & Alternative Income Trust (XFLT) and Broadcom (AVGO). Company Calendar Last Earnings8/14/2024Today10/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNYSE:VNRX CUSIPN/A CIK93314 WebN/A Phone646-650-1351Fax65 32 8172 5651Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$2.50 Low Stock Price Target$2.50 Potential Upside/Downside+242.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,320,000.00 Net Margins-3,318.42% Pretax Margin-3,355.68% Return on EquityN/A Return on Assets-165.21% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual Sales$770,000.00 Price / Sales87.29 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-6.63Miscellaneous Outstanding Shares92,100,000Free Float80,312,000Market Cap$67.21 million OptionableOptionable Beta1.09 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NYSE:VNRX) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.